Compare ALTI & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTI | TTRX |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | 490 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.9M | 298.8M |
| IPO Year | 2021 | 2025 |
| Metric | ALTI | TTRX |
|---|---|---|
| Price | $1.57 | $8.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 266.5K | 86.5K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $254,956,000.00 | N/A |
| Revenue This Year | $17.39 | N/A |
| Revenue Next Year | $9.19 | $900.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $1.25 | $2.60 |
| 52 Week High | $5.45 | $16.45 |
| Indicator | ALTI | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 37.87 |
| Support Level | N/A | $7.68 |
| Resistance Level | $3.97 | $11.17 |
| Average True Range (ATR) | 0.28 | 1.04 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 20.47 | 15.21 |
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.